CNO Financial Group, Inc.

CNO Financial Group, Inc. (CNO) Market Cap

CNO Financial Group, Inc. has a market capitalization of .

No quote data available.

CEO: Gary Chandru Bhojwani

Sector: Financial Services

Industry: Insurance - Life

IPO Date: 2003-09-10

Website: https://www.cnoinc.com

CNO Financial Group, Inc. (CNO) - Company Information

Market Cap: -|Sector: Financial Services

Company Profile

CNO Financial Group, Inc., through its subsidiaries, develops, markets, and administers health insurance, annuity, individual life insurance, and other insurance products for senior and middle-income markets in the United States. It offers Medicare supplement, supplemental health, and long-term care insurance policies; life insurance; and annuities, as well as Medicare advantage plans to individuals through phone, online, mail, and face-to-face. The company also focuses on worksite and group sales for businesses, associations, and other membership groups by interacting with customers at their place of employment. In addition, it provides fixed index annuities; fixed interest annuities, including fixed rate single and flexible premium deferred annuities; single premium immediate annuities; supplemental health products, such as specified disease, accident, and hospital indemnity products; and long-term care plans primarily to retirees and older self-employed individuals in the middle-income market. Further, the company offers universal life and other interest-sensitive life products; and traditional life policies that include whole life, graded benefit life, term life, and single premium whole life products, as well as graded benefit life insurance products. CNO Financial Group, Inc. markets its products under the Bankers Life, Washington National, and Colonial Penn brand names. The company sells its products through agents, independent producers, and direct marketing. CNO Financial Group, Inc. was founded in 1979 and is headquartered in Carmel, Indiana.

Analyst Sentiment

57%
Buy

From 5 Active Polls

1Y Forecast: $48.33

▲ +0.0% Potential Upside

Consensus Target Metrics

Low Bound

$47

Median

$48

High Bound

$50

Average

$48

Price & Moving Averages

Loading chart...

🎯 Wall Street Analyst Intelligence Report

1-Year structural target targets, chart projections, and sentiment maps.

Average 1Y Target
$48.33
▲ +0.88% Upside
Low Target
$47.00
-2% Risk
Median Target
$48.00
0% Mid
High Target
$50.00
4% Max
Consensus
Hold
7 / 17 Buys

Consensus Trend Projection

Trailing closures vs. 12-month metrics map.

Analyst Vote Distribution

Aggregate institutional coverage sentiment weights.

Historical valuation matrix unavailable.

📘 Full Research Report

ℹ️

AI-Generated Research: This report is for informational purposes only.

📘 CNO FINANCIAL GROUP INC (CNO) — Investment Overview

🧩 Business Model Overview

CNO is an insurance and retirement-services company focused on serving pre- and post-retirement customers, primarily through life, annuity, and Medicare-related health products. The business operates by (1) underwriting and pricing risk (mortality, morbidity, lapse/persistency), (2) collecting premiums and policyholder funds, (3) investing those funds in a diversified portfolio of high-quality assets, and (4) paying claims/benefits over the life of the policy. Profitability is driven by the spread between the yield earned on the general account and the cost of policyholder obligations, after underwriting/expense impacts and reserve development.

💰 Revenue Streams & Monetisation Model

Revenue and earnings generation are largely characterized by insurance cash flows and investment income rather than transaction volumes. Core monetisation channels include:

  • Net investment income: a recurring component driven by asset yields and credit quality, net of investment expenses and hedging/derivative activity (where applicable).
  • Insurance-related margins: spread economics and underwriting results on life and health products, including mortality/morbidity and persistency.
  • Policy fees and contract charges: for annuities and related retirement contracts, including account-based charges where contract design permits.

Margin drivers are primarily (a) the cost of policyholder liabilities (including lapse experience), (b) asset-liability management and the level of reinvestment yields, and (c) disciplined underwriting and claims management. For annuity-heavy models, surrender charges and product design can support persistency, improving the durability of investment spread capture.

🧠 Competitive Advantages & Market Positioning

CNO’s moat is best understood as a combination of insurance economics (liability cost management and asset-liability discipline) and distribution-linked switching frictions (persistency and contract terms).

  • Switching Costs / Persistency Effects (Annuities and Health): many retirement products incorporate surrender charges, declining early-withdrawal economics, and contract-specific terms that discourage rapid switching. For Medicare-related insurance, guaranteed-issue structures and underwriting rules shape customer behavior, supporting stable renewal patterns when products remain competitive.
  • Regulatory Moat / Capital Discipline: insurance is a capital-constrained business. State regulation, reserve requirements, risk-based capital frameworks, and statutory reporting create structural barriers that deter unseasoned entrants and constrain balance-sheet risk-taking.
  • Credit Culture and Underwriting Capability: durable results depend on underwriting accuracy and ongoing reserve adequacy, as well as careful general account credit selection. Competence here reduces earnings volatility and supports continued business writing.
  • Operational and Distribution Scale: CNO benefits from repeatable distribution and servicing processes suited to its customer base, which can lower per-policy acquisition and servicing costs relative to smaller or less specialized peers.

Competitive benchmarking (primary peers):

  • Lincoln Financial Group (LNC): broader life/annuity product set with strong retirement franchises; positioned differently across channels and product mix compared with CNO’s Medicare-focused health exposure and retirement contract mix.
  • Brighthouse Financial (BHF): emphasizes annuities and retirement solutions; competes for similar retirement-income demand, but the competitive vector differs where CNO’s Medicare supplement-related business changes the mix of risk and earnings drivers.
  • Mutual of Omaha (MOH): a prominent player in senior-focused insurance products; competes for Medicare-related customer segments, where CNO’s product design and underwriting/distribution approach aim to win persistency and profitability rather than simply maximize volume.

🚀 Multi-Year Growth Drivers

Over a 5–10 year horizon, CNO’s growth opportunity is anchored in demographic and retirement-income themes that support steady demand for insurance-based income solutions:

  • Age-Driven TAM expansion: the aging population sustains long-run demand for Medicare-related coverage and retirement products designed to provide lifetime or structured income.
  • Retirement income transition: households increasingly seek to convert retirement savings into more predictable income streams, supporting annuity and related retirement contract demand.
  • Persistency-led compounding: in insurance, durable earnings often compound through persistency and reinvestment of policyholder funds, not just new sales volume.
  • Premium and contract optimization: active portfolio management—product design, underwriting discipline, and asset-liability management—can improve risk-adjusted returns even when industry growth is moderate.

⚠ Risk Factors to Monitor

  • Interest rate and spread risk: insurance earnings can be pressured by sustained changes in yield curves, reinvestment rates, or the cost characteristics of liabilities; effective asset-liability management is critical.
  • Credit and market-value risk: deterioration in bond credit quality or wider credit spreads can affect investment income and impair the earnings power of the general account.
  • Regulatory and pricing risk (Medicare-related and insurance regulation): rate-setting frameworks, solvency rules, and compliance requirements can limit the ability to pass through costs or restructure reserves.
  • Longevity and morbidity variability: mortality and health claim experience can diverge from expectations, requiring reserve actions and disciplined product pricing.
  • Liquidity and capital adequacy: stress scenarios test statutory capital, dividend capacity, and the balance between growth and risk-based capital consumption.

📊 Valuation & Market View

Insurance equity valuation tends to focus less on simple operating multiples and more on balance-sheet quality and embedded earning power. Market participants typically anchor on:

  • Price-to-book and book value durability: how earnings translate into statutory and book value growth.
  • Earnings quality: persistence of investment spread and underwriting discipline, alongside reserve development credibility.
  • Embedded value / capital efficiency (framework-dependent): the degree to which new business and existing policy blocks translate into durable shareholder value given capital constraints.
  • Sensitivity to rates and credit: valuation often moves with expected future yields, credit spreads, and the perceived risk of reserve or capital strains.

Key drivers that move the needle are typically changes in expected investment yields, credit outlook, reserve adequacy confidence, and the ability to maintain persistency while competing on pricing and product terms.

🔍 Investment Takeaway

CNO’s long-term investment case rests on an insurance-focused moat: stable policyholder economics supported by persistency, regulatory-capital barriers, and operational underwriting/investment discipline. The business can compound through durable investment spread capture and demographic tailwinds for Medicare- and retirement-related products, provided credit quality, reserve adequacy, and asset-liability management remain intact through rate and credit cycles.


⚠ AI-generated — informational only. Validate using filings before investing.

📊 AI Financial Analysis

Powered by StockMarketInfo
Earnings Data: Q Ending 2026-03-31

"CNO reported Q1 2026 results with Revenue of $1.03B and Net Income of $37.7M (EPS $0.40). On an annual basis (vs. Q1 2025), revenue declined by -2.4% YoY ($1.03B vs. $1.00B) while net income increased by +175.5% YoY ($37.7M vs. $13.7M). Sequentially (vs. Q4 2025), revenue fell by -9.9% QoQ ($1.15B to $1.03B) and net income fell by -59.4% QoQ ($92.9M to $37.7M). Profitability improved materially versus a year ago: net margin increased to 3.7% from 1.4% YoY, but operating and net margins were lower than Q4. Gross margin rose to 44.6% from 35.2% YoY, yet the company’s QoQ profit compression is evident—net margin dropped from 8.1% in Q4 to 3.7% in Q1. Balance sheet resilience appears reasonable for a financial services insurer: total assets were $38.9B, with equity at $2.50B, broadly stable QoQ ($2.64B in Q4), and long-term debt at $4.30B. Cash flow metrics are presented as 0 for Q1 due to dataset limitations, so quarter-level cash generation quality cannot be confirmed here; however, dividends were not paid in Q1 (payout dynamics look variable). Shareholder returns based on the provided market data were solid: the stock is up +14.6% over 1Y (below the 20% momentum threshold). Total value drivers thus look more valuation/earnings execution than outsized momentum, while analyst targets imply modest upside (consensus $46.67 vs. ~$43.63)."

Revenue Growth

Caution

Revenue was $1.03B in Q1 2026: -2.4% YoY and -9.9% QoQ, indicating a contracting top line sequentially.

Profitability

Positive

Net margin improved sharply YoY (3.7% vs. 1.4%), but profitability contracted QoQ (net margin 3.7% vs. 8.1% in Q4). EPS was $0.40 vs. $0.14 YoY.

Cash Flow Quality

Fair

Q1 cash flow fields show net cash from operating activities as 0 in the dataset, limiting assessment of cash generation quality; dividends were 0 in Q1.

Leverage & Balance Sheet

Positive

Total assets were $38.9B with equity around $2.50B; long-term debt was $4.30B. Leverage appears manageable, though equity slipped QoQ.

Shareholder Returns

Neutral

1Y price gain is +14.6% (not >20% momentum). Dividend yield is ~0.44% per the provided ratio; buybacks are not captured in Q1.

Analyst Sentiment & Valuation

Neutral

Consensus target ($46.67) is above the current price (~$43.63), implying modest upside; valuation implies expectations of ongoing profitability normalization.

Disclaimer:This analysis is AI-generated for informational purposes only. Accuracy is not guaranteed and this does not constitute financial advice.

Fundamentals Overview

Loading fundamentals overview...

CNO delivered strong Q1 2026 operating performance with operating EPS of $1.05 (+33% YoY; +42% excluding significant items), supported by 11% higher total new annualized premiums and continued distribution traction (fifteenth consecutive sales growth; thirteenth producing-agent-count growth). Profitability benefited from underwriting strength, investment growth (net investment income +6% YoY, driven by higher net investment income and yields above 6% for thirteen consecutive quarters), and disciplined expense/capital management (18.9% expense ratio aided by lower-than-planned spending). Management affirmed full-year 2026 guidance and highlighted capital flexibility: $280M holding liquidity, RBC within 360%–390% target range, and debt/capital of 26.4%. Key risks discussed were modestly adverse MedSup claims experience requiring 2026 rate increases, negative FABN arbitrage limiting issuance, and potential noise to RBC from equity-market volatility—expected to normalize as markets recover. MedSup pricing provides a clear near-term earnings lever into Q4 2026.

AI IconGrowth Catalysts

  • Total new annualized premiums up 11% (across both Consumer and Worksite divisions)
  • Consumer: Life and Health NAP up 9% YoY for the quarter; Total Health NAP up 20% with Supplemental health up 10%
  • Medicare supplement momentum: Total Medicare policies sold up 24% and Medicare supplement NAP up 53%
  • Worksite: Life and Health NAP up 22% with life insurance up 56%, hospital indemnity up 121%, accident up 18%
  • D2C life channel productivity: non-television lead sources generated nearly 65% of all D2C life sales in the quarter
  • Brokerage growth: client assets up 27% to a new record; total accounts up 13%; total client assets >$18B up 12% when combining with annuity account values

Business Development

  • Partnerships not explicitly named; distribution relies on exclusive middle-market focus with a captive agent distribution model
  • AI-enabled “Colonial Penn” call center initiative to route customer calls to live agents (platform/process development rather than a named partner)

AI IconFinancial Highlights

  • Operating EPS $1.05: up 33% YoY; up 42% excluding significant items
  • Sales momentum: 15th consecutive quarter of sales growth; total new annualized premiums +11%
  • Expense ratio 18.9%: reflecting lower-than-planned spending; management expects normalization over the balance of the year
  • Deployed $60 million of excess capital on share repurchases; weighted average diluted shares outstanding reduced 7%
  • Net investment income +6% YoY; tenth consecutive quarter of growth
  • Net investment income driven by net insurance liabilities/assets +4.8% in the quarter and thirteen consecutive quarters of new money rates above 6%
  • Medicare supplement: faced modestly adverse claims experience, partially offset by favorable impact of continued growth; management expects rate increases in 2026 to address claims experience
  • First quarter seasonality: first quarter typically lowest insurance product margin quarter; management notes Q1 results solid despite seasonality

AI IconCapital Funding

  • Share repurchases: $60 million in the quarter
  • Capital returned to shareholders: $77 million in the quarter
  • Consolidated risk-based capital (RBC) ratio well within target 360%–390%
  • Holding company liquidity: $280 million vs $150 million minimum target
  • Debt to capital: 26.4% within target range 25%–28%

AI IconStrategy & Ops

  • AI adoption: using AI in Colonial Penn call center to shorten customer wait times and increase sales conversion quality
  • Technology/data/AI roadmap initiatives moving from pilot to execution across the company
  • Expense management: measured capital and expense discipline while reinvesting to support growth
  • Expense ratio timing impact: first quarter higher expenses typically; this year lower-than-planned spending resulted in a lower-than-planned expense ratio

AI IconMarket Outlook

  • 2026 guidance: affirms original guidance; no numeric revision provided
  • ROR target framework: credibility built through delivery; intends to update ROE objectives for 2027 and beyond no later than early next year
  • ROE commentary: management expects ROE likely to increase in 2027 vs prior ambitions (no updated target number given)

AI IconRisks & Headwinds

  • Medicare supplement claims experience modestly adverse in Q1; management expects 2026 rate increases to address
  • Credit market/FABN spread environment: negative basic arbitrage during Q1 reduced incentive to issue; reassess next window likely in June
  • Equity market volatility impacts RBC: S&P down ~5% in the quarter lowered FIAs/interest-sensitive life reserves and call option assets similarly, but statutory reserve floors created noise (lower surplus/RBC/dividend capacity); management expects recovery unwinds over time
  • First-quarter seasonality: typically lowest insurance product margin quarter of the year (managed expectation risk)

Q&A: Analyst Interest

  • Topic: MedSup rate increase timing and premium “kick-in” for closed vs open blocks: Management explained 2025 filings in two buckets—closed block 10.5% (01/01/2026 effective) approved 10.2% and open block 16.8% filed effective 07/01/2026 expected ~14.5% approvals—earning in over time with full quarterly impact by Q4 2026.
  • Topic: Expenses normalization—whether the low Q1 expense ratio is timing-only: Management stated Q1 typically has higher expenses and thus a higher expense ratio that grades down. They said expectations were not met, but full-year expenses are still expected to land around the original plan; business growth should provide favorable denominator leverage.
  • Topic: Credit/FABN issuance opportunities under changing spreads: Management described financials widening vs industrials in Q1, creating negative basic arbitrage for FABN transactions, so issuance would not add much while risking target ROE. They emphasized reassessment into a likely June window and no pressure to issue unless targets can be met without harming risk/quality.

Sentiment: MIXED

Note: This summary was synthesized by AI from the CNO Q1 2026 earnings transcript. Financial data is complex; please verify all metrics against official SEC filings before making investment decisions.

Loading financial data and tables...
© 2026 Stock Market Info — CNO Financial Group, Inc. (CNO) Financial Profile